HeraMED Ltd
HMD
Company Profile
Business description
HeraMED Ltd is engaged in developing, connected pregnancy monitoring solutions for home and professional use. It has developed a foetal heartbeat monitor called HeraBEAT which is a medical-grade, clinically-validated, smart and connected Ultrasound Foetal Doppler device predominantly for use by an expectant mother to self-monitor her foetus' heart rate (FHR). It is also focused on the commercialization and deployment of its HeraCARE pregnancy monitoring solution. Geographically, the company generates a majority of its revenue from the United States of America followed by Australia and Israel.
Contact
201, 697 Burke Road
Suite 4
CamberwellVIC3124
AUST: +61 272511888
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2025
Employees
Stocks News & Analysis
stocks
What next for the largest company on the ASX?
After a historic rally in 2024, what lies ahead for this overvalued banking titan?
stocks
Ask the analyst: Are IDP Education's woes temporary?
The global education services provider has gone from stock market darling to one of the ASX's weakest performers. What gives?
stocks
Is it time to buy the Magnificent Seven?
After the recent selloff, the bull market’s most in-demand stocks look much cheaper.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,013.30 | 10.70 | 0.13% |
| CAC 40 | 8,028.28 | 90.07 | 1.13% |
| DAX 40 | 22,986.82 | 419.68 | 1.86% |
| Dow JONES (US) | 41,436.70 | 623.13 | 1.53% |
| FTSE 100 | 8,632.33 | 89.77 | 1.05% |
| HKSE | 23,959.98 | 359.67 | 1.52% |
| NASDAQ | 17,717.81 | 414.79 | 2.40% |
| Nikkei 225 | 37,053.10 | 234.01 | 0.64% |
| NZX 50 Index | 12,266.25 | 57.20 | 0.47% |
| S&P 500 | 5,627.96 | 106.44 | 1.93% |
| S&P/ASX 200 | 7,789.70 | 3.50 | 0.04% |
| SSE Composite Index | 3,419.56 | 60.83 | 1.81% |